
Non-adherence may be a reason why your patients continue to have elevated LDL-C—increasing their CVD risk.
The effect of LEQVIO® on cardiovascular morbidity and mortality has not been determined.



*From an analysis of a large IQVIA open claims dataset of patients (N=72,001) between September 2020 and January 2023.
†In a retrospective cohort study of pharmacy and health plan claims of patients who initiated PCSK9 mAb (N=13,151) between January 1, 2016 and June 30, 2016 who were followed for a minimum of 6 months following their first prescription fill. Discontinuation was defined as the gap of 60 days or more between the last day of supply of one prescription and the start of the next prescription. Specific reasons for discontinuation were unknown; however, it could have been due to poor tolerability, noncompliance, unwillingness to perform injections, and insurance or cost issues. Gaps in therapy were derived from actual prescription fill data.
mAb, monoclonal antibody.
-
PREFER
FEWER
INJECTIONS -
STRUGGLE
TO TAKE
MEDICATIONS -
WORRY
ABOUT
COST

Patients like Tony may
need something more, yet
PREFER FEWER INJECTIONS

Patients like Tony may
need something more, yet
PREFER FEWER INJECTIONS
• Find frequent injections a hassle
• Dislike the idea of giving themselves a shot
• Persistently elevated LDL-C
• Find frequent injections a hassle
• Dislike the idea of giving themselves a shot
• Persistently elevated LDL-C
Age: 65
Insurance: Traditional
Medicare + Supplemental
LDL-C level:
Baseline: 180 mg/dL
Current: 120 mg/dL
Current LDL-C treatment:
Atorvastatin 80 mg
(increased from 40 mg
1 month ago)
Medical history:
-
• CV events: NSTEMI and PCI 3 months ago
-
• Additional health conditions: Hypertension, metabolic syndrome, osteoarthritis
OFFERS PATIENTS THE CHOICE OF ONLY 2 INJECTIONS A YEAR‡ WITH LEQVIO1
• HCP-administered, eliminating need for self injection1
• 2 doses of LEQVIO* vs 12-26 self injections of PCSK9 mAbs per year1,14 §
‡After 2 initial doses and taken with statin therapy.1
§This is not a complete list of all the available treatments for patients with primary hyperlipidemia who have elevated LDL-C. The comparison pertains only to differences in dosing and administration and should not be considered a comparison of efficacy or safety.
SEE HOW LEQVIO DOSING CAN
HELP PATIENTS LIKE TONY

Patients like Robert may
need something more, yet
STRUGGLE TO TAKE
THEIR MEDICATIONS
AS PRESCRIBED

Patients like Robert may need something more, yet
STRUGGLE TO TAKE THEIR MEDICATIONS AS PRESCRIBED
• Don't want to take another pill
• Reluctant to add to at-home treatment burden
• Persistently elevated LDL-C
• Don't want to take another pill
• Reluctant to add to at-home treatment burden
• Persistently elevated LDL-C
Age: 55
Insurance: Commercial
LDL-C level:
Baseline: 160 mg/dL
Current: 105 mg/dL
Current LDL-C treatment:
Rosuvastatin 40 mg
(increased from 20 mg
8 months ago)
Medical history:
-
• CV events: Unstable angina 2 years ago due to CAD
-
• Additional health conditions: Hypertension, diabetes

LEQVIO® IS HCP-ADMINISTERED, SO
YOU KNOW YOUR PATIENTS GET
THEIR DOSE1
• HCP-administered, requiring less additional at-home efforts of patients1
• No added therapies to take or inject at home1
CAD, coronary artery disease; CV, cardiovascular.
SEE HOW LEQVIO DOSING CAN
HELP PATIENTS LIKE ROBERT

Patients like Carla may
need something more, yet
WORRY ABOUT THE
COST OF ANOTHER
MEDICATION

Patients like Carla may need something more, yet
WORRY ABOUT THE COST OF ANOTHER MEDICATION
• Already paying for multiple therapies
• Retired and relies on a fixed income
• Persistently elevated LDL-C
• Already paying for multiple therapies
• Retired and relies on a fixed income
• Persistently elevated LDL-C
Age: 70
Insurance: Traditional
Medicare
+ Supplemental
LDL-C level:
Baseline: 200 mg/dL
Current: 120 mg/dL
Current LDL-C treatment:
Pravastatin 40 mg + ezetimibe 10 mg (has been modifying statin therapy due to muscle aches)
Medical history:
-
• CV events: STEMI 1 year ago, PAD
-
• Additional health conditions: Hypertension, osteoporosis, atrial fibrillation

TWICE-YEARLY‡ LEQVIO® IS AFFORDABLE FOR MOST PATIENTS.1
• 80% of Medicare patients have supplemental plans and pay as little as $04
• 65% of Commercial & Medicare patients† may pay as little as $04§
• Not subject to the Medicare Part D donut hole4
‡After 2 initial doses and taken with statin therapy.1
§Includes all insurance types: Traditional Medicare, Medicare Advantage, and Commercial plans. Based on data up to July 2023.
PAD, peripheral artery disease; STEMI, ST-elevation myocardial infarction.
SEE HOW LEQVIO IS AFFORDABLE
FOR MOST PATIENTS
LOOKING FOR MORE
INFORMATION FOR YOUR
PATIENTS?
THERE'S MORE TO
KNOW ABOUT LEQVIO
See what LEQVIO can do for patients like yours
STUDY CLINICAL DATA
ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery
disease; CV, cardiovascular; LDL-C, low-density
lipoprotein cholesterol;
mAb, monoclonal antibody; MI, myocardial infarction; PAD, peripheral
arterial disease; PCI,
percutaneous coronary intervention; PCSK9,
proprotein convertase subtilisin/kexin type 9; STEMI, ST-elevation
myocardial infarction.